Ascentage Pharma's Key Drug Candidates Highlighted in Five Studies at EHA 2024 Congress

SUZHOU, China and ROCKVILLE, Md., May 15, 2024 – Ascentage Pharma, a global biopharmaceutical company focusing on novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced that its recent findings from five studies have been selected for poster presentations at the 2024 European Hematology Association Hybrid Congress (EHA 2024). These studies involve olverembatinib (HQP1351), lisaftoclax (APG-2575), and APG-5918.

The European Hematology Association (EHA) Hybrid Congress is Europe's largest hematology conference, attracting over 10,000 specialists and researchers from more than 100 countries annually. This year's congress is scheduled for June 13 - 16, 2024, in Madrid, Spain.

Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, expressed enthusiasm about presenting the company’s advancements in hematology. Highlighting the potential of their drug candidates in treating chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), multiple myeloma (MM), immunoglobulin light-chain (AL) amyloidosis, and anemia-related diseases, Dr. Zhai emphasized the importance of these findings for future therapeutic developments.

The five studies to be presented at EHA 2024 include:

Olverembatinib Highlights:
1. Overcoming Resistance in CML and Ph+ ALL: This study shows olverembatinib's ability to overcome resistance to ponatinib and asciminib in heavily pretreated patients. The poster (Abstract#: P722) will be presented by Dr. Elias Jabbour from The University of Texas MD Anderson Cancer Center on June 14, 2024, from 18:00 to 19:00 CEST.

2. Combination Therapy for Ph+ ALL: Another study explores the combination of third-generation TKI olverembatinib with chemotherapy or blinatumomab for newly diagnosed adult Ph+ ALL patients. Junjie Chen from Nanfang Hospital, Southern Medical University, will present this poster (Abstract#: P427) on June 14, 2024, from 18:00 to 19:00 CEST.

3. Patient Reported Outcomes: Lu Yu from Peking University People's Hospital will present findings on the outcomes in adults with TKI-resistant CML receiving olverembatinib therapy. This e-poster (Abstract#: P1862) will be available on June 14, 2024, from 18:00 to 19:00 CEST.

Lisaftoclax Study:
- Combination Treatments for R/R MM and AL Amyloidosis: Dr. Sikander Ailawadhi from Mayo Clinic Florida will present this study (Abstract#: P917), showcasing lisaftoclax combined with novel therapeutic regimens for patients with relapsed or refractory multiple myeloma (MM) or immunoglobulin light-chain (AL) amyloidosis. The presentation is scheduled for June 14, 2024, from 18:00 to 19:00 CEST.

APG-5918 Research:
- Improving Anemia in CKD Models: Dr. Eric Liang from Ascentage Pharma Group Inc. will present the study (Abstract#: P1550) on how the EED inhibitor APG-5918 improves hemoglobin insufficiency in preclinical models of anemia induced by chronic kidney disease. This poster will also be available on June 14, 2024, from 18:00 to 19:00 CEST.

About Ascentage Pharma:
Ascentage Pharma (6855.HK) is dedicated to developing therapies for cancer, chronic hepatitis B, and age-related diseases. Listed on the Hong Kong Stock Exchange in 2019, the company focuses on compounds that inhibit protein-protein interactions to restore apoptosis. With a pipeline of nine clinical drug candidates, the company is leading in targeting all three known classes of apoptosis regulators. Ascentage Pharma conducts over 40 Phase I/II clinical trials globally and has received numerous designations for its investigational drugs, including Orphan Drug and Fast Track designations from the US FDA.

With a strong R&D team and multiple global partnerships, Ascentage Pharma aims to address unmet clinical needs worldwide, continuously advancing its clinical programs to benefit patients globally.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!